Tirzepatide dosage chart

Reconstitution steps

1. 1Draw 3mL of bacteriostatic water into a sterile syringe.
2. 2Inject the water slowly down the inside wall of the 30MG Tirzepatide vial.
3. 3Swirl gently until fully dissolved — do not shake.
4. 4Use a U-100 insulin syringe for accurate dosing.
5. 5Store reconstituted solution refrigerated at 2–8 °C, protected from light.

Spartan Peptides official protocol

Higher doses may be split into multiple injections. Dosing advice: start low and move up once a week.

• Mixing guide: mix 30MG Tirzepatide with 3mL BAC water.
• Concentration after mixing: 10 mg/mL (1 unit = 0.1mg).
• Recommended dosage: 0.5mg – 15mg (recommended dosage range).
• Injection frequency: 1x per week shot, or split the dose 2x per week.
• Use an insulin syringe (U-100) for accurate dosing.

Reported research focus

Research purposes only. Premium quality. Built on legacy. Backed by science.

• Supports weight management*
• Supports metabolic health*
• Improves insulin sensitivity*

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
• All doses through 10 mg/week fit in a single 1 mL syringe at this concentration.
• Inject slowly; wait a few seconds before withdrawing the needle.
• Document weekly dose, date, and injection site to maintain consistency.
• Gastrointestinal effects (nausea, diarrhea) are common initially; gradual titration helps minimize them.

How This Works

Tirzepatide is a novel dual agonist that simultaneously activates GLP‑1 (glucagon‑like peptide‑1) and GIP (glucose‑dependent insulinotropic polypeptide) receptors. This dual mechanism enhances glucose‑dependent insulin secretion while suppressing glucagon release, slowing gastric emptying, and promoting satiety through central appetite regulation. The added GIP activity appears to synergistically amplify metabolic effects beyond GLP‑1 alone, contributing to superior weight reduction observed in clinical trials. Its ~5‑day half‑life enables convenient once‑weekly administration.

Potential Benefits & Side Effects

Observations from clinical trials and published literature.

• Glycemic control: Significant HbA1c reductions in type 2 diabetes trials.
• Weight reduction: Clinical trials report substantial body‑weight loss (up to ~11 kg more than GLP‑1 RA comparators over 26 weeks at higher doses).
• Cardiovascular markers: Improvements in lipid profiles and blood pressure observed in some studies.
• Common side effects: Gastrointestinal (nausea, diarrhea, vomiting, constipation) — typically mild‑to‑moderate and dose‑dependent; gradual titration reduces incidence.
• Injection‑site reactions: Occasional mild redness or irritation at subcutaneous injection sites.

Lifestyle Factors

Complementary strategies for best outcomes.

• Pair with a balanced, calorie‑appropriate diet; reduced appetite may naturally decrease intake.
• Prioritize protein to preserve lean mass during weight loss.
• Combine resistance training and aerobic activity to support metabolic health.
• Stay hydrated, especially given potential gastrointestinal effects.
• Prioritize sleep and stress management to support adherence and recovery.

Injection Technique

General subcutaneous guidance from clinical best‑practice resources.

• Clean the vial stopper and skin with alcohol; allow to dry.
• Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
• Do not aspirate for subcutaneous injections; inject slowly and steadily.
• Rotate sites systematically (abdomen avoiding 2‑inch radius around navel, outer thighs, upper arms) to avoid lipohypertrophy.
• Dispose of needles and syringes in a sharps container immediately after use.

important-note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.

Tirzepatide dosage FAQs